ash 2018: dara/rev/dex/velcade for newly diagnosed multiple myeloma patients
Published 5 years ago • 586 plays • Length 1:38Download video MP4
Download video MP3
Similar videos
-
6:12
ash 2018: using daratumumab early with standard myeloma combos for newly diagnosed patients
-
7:31
clinical trial: darzalex (daratumamab) with revlimid/velcade/dex for newly diagnosed myeloma
-
2:27
ash 2018: dara velcade dex with or without venetoclax
-
2:09
ash 2018: deter - dara rev dex for high-risk smoldering myeloma
-
8:26
ash 2018: selinexor, daratumumab and dexamethasone for relapsed/refractory myeloma
-
7:59
real world evidence for myeloma patients on (ird) ixaxomib/lenalidomide/dex | ash 2021
-
16:11
all about velcade (bortezomib) for myeloma patients
-
14:28
all about darzalex (daratumumab)
-
2:28
dara, len & dex for newly-diagnosed myeloma
-
1:34
ash 2018: isatuximab in relapsed or refractory multiple myeloma
-
3:01
results of using dara-cybord to treat patients with newly diagnosed or relapsed multiple myeloma
-
6:14
results of iberdomide in combination with dex and daratumumab or bortezomib in patients with rrmm
-
2:07
fda approved new 4-drug combo for newly diagnosed myeloma patients | important info you should know!
-
3:52
analysis of different clinical scenarios using daratumumab | rafael fonseca, md | ash 2021
-
8:16
daratumumab, carfilzomib, lenalidomide and dex for hr smoldering multiple myeloma: ascent trial
-
3:23
ash 2019: melflufen dex — horizon trial update | dr. agne paner
-
6:44
carfilzomib 2x weekly in combination with dex and daratumumab vs dara with bortezomib and dex
-
14:31
isatuximab len/dex/bortezomib vs isard in newly diagnosed transplant ineligible multiple myeloma
-
1:00:47
using daratumumab to treat high-risk myeloma patients